BC
ALXN

Broadfin Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Broadfin Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$8.99M Buy
+83,100
New +$8.89M 1.2% 24
2019
Q1 		– Sell
-58,700
Closed -$5.71M – 52
2018
Q4 		$5.71M Buy
+58,700
New +$6.94M 0.75% 31

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Broadfin Capital's ALXN Position: Q4 2019 in Review

Broadfin Capital opened a new position in Alexion Pharmaceuticals (ALXN) in Q4 2019: 83,100 shares worth $8.99M. The stake represents 1.2% of the portfolio and ranks #24 among its holdings. This is a return to the name: Broadfin Capital previously reported a position in ALXN as recently as Q4 2018.

Broadfin Capital first reported a position in ALXN in Q4 2018 and has held it in 2 quarters since. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Broadfin Capital held 83,100 shares of Alexion Pharmaceuticals worth $8.99M as of Q4 2019.
  • Alexion Pharmaceuticals was a new Broadfin Capital position in Q4 2019.
  • Alexion Pharmaceuticals made up 1.2% of Broadfin Capital's portfolio in Q4 2019, its #24 holding.
  • Broadfin Capital first reported a position in Alexion Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.